EDMI and PLUS ES set to transform energy infrastructure across Australia

EDMI and PLUS ES set to transform energy infrastructure across Australia

BRISBANE, Australia, Dec. 18, 2025 /PRNewswire/ -- EDMI, a global leader in intelligent energy solutions, has entered into a landmark agreement with PLUS ES, a leading smart meter and energy infrastructure provider in Australia, setting a new...

MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics

MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics

SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance...

MetaOptics Provides Year-End Business Review and Update

MetaOptics Provides Year-End Business Review and Update

SINGAPORE, Dec. 17, 2025 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) ("MetaOptics" or the "Company", and together with its subsidiaries, the "Group") As we approach the Christmas festive season and the close of 2025, MetaOptics would like to...

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...

Execution of Additional Financing Agreement for Rooftop Solar Power Project in Singapore

Execution of Additional Financing Agreement for Rooftop Solar Power Project in Singapore

TOKYO, Dec. 17, 2025 /PRNewswire/ -- Tokyo Electric Power Company Holdings, Inc. (hereinafter "TEPCO HD") is pleased to announce that, on December 4, 2025, a Special Purpose Vehicle (hereinafter "SPV") jointly established by TEPCO HD and ESR Group...

Carrier Announces Agreement to Sell Riello to Ariston Group

Carrier Announces Agreement to Sell Riello to Ariston Group

PALM BEACH GARDENS, Fla., Dec. 17, 2025 /PRNewswire/ -- Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions, today announced that it has entered into a definitive agreement to sell its Riello business...

Youlife Group Inc. Announces Non-Binding Letter of Intent as It explores Strategic Expansion in China's Blue-Collar Service Market

Youlife Group Inc. Announces Non-Binding Letter of Intent as It explores Strategic Expansion in China's Blue-Collar Service Market

BEIJING, Dec. 12, 2025 /PRNewswire/ -- Youlife Group Inc. ("Youlife" or the "Company") (NASDAQ: YOUL), a leading blue-collar lifetime service provider in China, today announced that it has entered into a non-binding letter of intent (the "LOI"),...

Yum China Announces US$460 Million Share Repurchase Agreements for First Half of 2026 as Part of US$1.5 Billion Full-Year Capital Return Plan

Yum China Announces US$460 Million Share Repurchase Agreements for First Half of 2026 as Part of US$1.5 Billion Full-Year Capital Return Plan

SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- Yum China Holdings, Inc. (the "Company" or "Yum China") (NYSE: YUMC and HKEX: 9987) announced that it has entered into share repurchase agreements in the U.S. and Hong Kong for an aggregate repurchase amount...

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization - Exclusive Greater China license to develop and...

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company...

  • 1
  • 2
  • 3
  • 4
  • 5
  • menu
    menu